Anti-inflammatory effects of the Activation of the angiotensin-(1-7) receptor, mas, in experimental models of arthritis

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5569-5576

  Da Silveira, Kátia Daniela ^a,b   Coelho, Fernanda Matos ^b   Vieira, Angélica Thomáz ^b   Sachs, Daniela ^b   Barroso, Lívia Corrêa ^b   Costa, Vivian Vasconcelos ^b   Bretas, Thales Lages Bicalho ^b   Bader, Michael ^c   De Sousa, Lirlândia Pires ^a,b   Da Silva, Tarcília Aparecida ^a   Dos Santos, Robson Augusto Souza ^a   E Silva, Ana Cristina Simões ^d   Teixeira, Mauro Martins ^b  

^a Institute of Biological Sciences   (Brazil)

^b Group of Neuroimmunology   (Brazil)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; ANTIGEN; CXCL1 CHEMOKINE; CYTOKINE; INTERLEUKIN 1BETA; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; ONCOPROTEIN; PROTO ONCOGENE PROTEINS C MAS 1; PROTO-ONCOGENE PROTEINS C-MAS-1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EDEMA; FEMALE; HISTOPATHOLOGY; INFLAMMATION; JOINT; LEUKOCYTE ADHERENCE; MALE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; WILD TYPE; ANIMAL; ARTHRITIS; C57BL MOUSE; DRUG POTENTIATION; IMMUNOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; FEMALE; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 78149482692     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000314     Document Type: Article

References (56)

1. Zaman, M. A., S. Oparil, and D. A. Calhoun. 2002. Drugs targeting the reninangiotensin-aldosterone system. Nat. Rev. Drug Discov. 1:621-636.
2. Ruiz-Ortega, M., O. Lorenzo, Y. Suzuki, M. Rupérez, and J. Egido. 2001. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 10:321-329.
3. Owen, C. A., and E. J. Campbell. 1998. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J. Immunol. 160:1436-1443.
4. Gomez, R. A., L. L. Norling, N. Wilfong, P. Isakson, K. R. Lynch, R. Hock, and P. Quesenberry. 1993. Leukocytes synthesize angiotensinogen. Hypertension 21:470-475.
5. Walsh, D. A., P. I. Mapp, J. Wharton, J. M. Polak, and D. R. Blake. 1993. Neuropeptide degrading enzymes in normal and inflamed human synovium. Am. J. Pathol. 142:1610-1621.
6. Walsh, D. A., T. Suzuki, G. A. Knock, D. R. Blake, J. M. Polak, and J. Wharton. 1994. AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br. J. Pharmacol. 112:435-442.
7. Kranzhöfer, R., M. Browatzki, J. Schmidt, and W. Kübler. 1999. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem. Biophys. Res. Commun. 257:826-828.
8. Tham, D. M., B. Martin-McNulty, Y. X. Wang, D. W. Wilson, R. Vergona, M. E. Sullivan, W. Dole, and J. C. Rutledge. 2002. Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol. Genomics 11:21-30.
9. Firestein, G. S. 2004. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J. Clin. Invest. 114:471-474.
10. Dalbeth, N., J. Edwards, S. Fairchild, M. Callan, and F. C. Hall. 2005. The nonthiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 44:24-31.
11. Martin, M. F., K. E. Surrall, F. McKenna, J. S. Dixon, H. A. Bird, and V. Wright. 1984. Captopril: a new treatment for rheumatoid arthritis? Lancet 323:1325-1328.
12. Price, A., J. C. Lockhart, W. R. Ferrell, W. Gsell, S. McLean, and R. D. Sturrock. 2007. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. Arthritis Rheum. 56:441-447.
13. Ferrario, C. M., and M. C. Chappell. 2004. Novel angiotensin peptides. Cell. Mol. Life Sci. 61:2720-2727.
14. Simões e Silva, A. C., S. V. Pinheiro, R. M. Pereira, A. J. Ferreira, and R. A. Santos. 2006. The therapeutic potential of angiotensin-(1-7) as a novel renin-angiotensin system mediator. Mini Rev. Med. Chem. 6:603-609.
15. Santos, R. A., A. J. Ferreira, and A. C. Simões E Silva. 2008. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp. Physiol. 93:519-527.
16. Tipnis, S. R., N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner. 2000. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275:33238-33243.
17. Donoghue, M., F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, N. Stagliano, M. Donovan, B. Woolf, K. Robison, R. Jeyaseelan, et al. 2000. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87: E1-E9.
18. Santos, R. A., A. C. Simoes e Silva, C. Maric, D. M. Silva, R. P. Machado, I. de Buhr, S. Heringer-Walther, S. V. Pinheiro, M. T. Lopes, M. Bader, et al. 2003. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 100:8258-8263.
19. Young, D., G. Waitches, C. Birchmeier, O. Fasano, and M. Wigler. 1986. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45:711-719.
20. Rabin, M., D. Birnbaum, D. Young, C. Birchmeier, M. Wigler, and F. H. Ruddle. 1987. Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements. Oncogene Res. 1:169-178.
21. Zohn, I. E., M. Symons, M. Chrzanowska-Wodnicka, J. K. Westwick, and C. J. Der. 1998. Mas oncogene signaling and transformation require the small GTP-binding protein Rac. Mol. Cell. Biol. 18:1225-1235.
22. Wiemer, G., L. W. Dobrucki, F. R. Louka, T. Malinski, and H. Heitsch. 2002. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40:847-852.
23. Faria-Silva, R., F. V. Duarte, and R. A. Santos. 2005. Short-term angiotensin (1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 46:948-952.
24. Lemos, V. S., D. M. Silva, T. Walther, N. Alenina, M. Bader, and R. A. Santos. 2005. The endothelium-dependent vasodilator effect of the nonpeptide Ang (1-7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J. Cardiovasc. Pharmacol. 46:274-279.
25. Pinheiro, S. V., A. C. Simões e Silva, W. O. Sampaio, R. D. de Paula, E. P. Mendes, E. D. Bontempo, J. B. Pesquero, T. Walther, N. Alenina, M. Bader, et al. 2004. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44:490-496.
26. Benter, I. F., M. H. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz. 2006. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. Am. J. Physiol. Heart Circ. Physiol. 290: H684-H691.
27. Coelho, F. M., V. Pinho, F. A. Amaral, D. Sachs, V. V. Costa, D. H. Rodrigues, A. T. Vieira, T. A. Silva, D. G. Souza, R. Bertini, et al. 2008. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis Rheum. 58:2329-2337.
28. Barsante, M. M., E. Roffê, C. M. Yokoro, W. L. Tafuri, D. G. Souza, V. Pinho, M. S. Castro, and M. M. Teixeira. 2005. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur. J. Pharmacol. 516:282-289.
29. Francischi, J. N., C. M. Yokoro, S. Poole, W. L. Tafuri, F. Q. Cunha, and M. M. Teixeira. 2000. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur. J. Pharmacol. 399:243-249.
30. Sousa, L. P., B. S. Brasil, Bde. M. Silva, S. V. Nogueira, A. A. Andrade, P. C. Ferreira, S. M. Teixeira, K. J. Gollob, E. G. Kroon, K. Kato, and C. A. Bonjardim. 2005. Characterization of a-enolase as an interferon-a2a1 regulated gene. Front. Biosci. 10:2534-2547.
31. Williams, A. S., P. J. Richards, E. Thomas, S. Carty, M. A. Nowell, R. M. Goodfellow, C. M. Dent, B. D. Williams, S. A. Jones, and N. Topley. 2007. Interferon-g protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis Rheum. 56:2244-2254.
32. Cunha, T. M., W. A. Verri, Jr., G. G. Vivancos, I. F. Moreira, S. Reis, C. A. Parada, F. Q. Cunha, and S. H. Ferreira. 2004. An electronic pressuremeter nociception paw test for mice. Braz. J. Med. Biol. Res. 37:401-407.
33. Krege, J. H., J. B. Hodgin, J. R. Hagaman, and O. Smithies. 1995. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115.
34. Veihelmann, A., G. Szczesny, D. Nolte, F. Krombach, H. J. Refior, and K. Messmer. 1998. A novel model for the study of synovial microcirculation in the mouse knee joint in vivo. Res. Exp. Med. (Berl.) 198:43-54.
35. Iyer, S. N., C. M. Ferrario, and M. C. Chappell. 1998. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31:356-361.
36. Grobe, J. L., A. P. Mecca, H. Mao, and M. J. Katovich. 2006. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am. J. Physiol. Heart Circ. Physiol. 290: H2417-H2423.
37. Mateo, T., Y. N. Abu Nabah, M. Abu Taha, M. Mata, M. Cerdá- Nicolás, A. E. Proudfoot, R. A. Stahl, A. C. Issekutz, J. Cortijo, E. J. Morcillo, et al. 2006. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J. Immunol. 176:5577-5586.
38. Nabah, Y. N., T. Mateo, R. Estellés, M. Mata, J. Zagorski, H. Sarau, J. Cortijo, E. J. Morcillo, P. J. Jose, and M. J. Sanz. 2004. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110:3581-3586.
39. Barsante, M. M., T. M. Cunha, M. Allegretti, F. Cattani, F. Policani, C. Bizzarri, W. L. Tafuri, S. Poole, F. Q. Cunha, R. Bertini, and M. M. Teixeira. 2008. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br. J. Pharmacol. 153:992-1002.
40. Grespan, R., S. Y. Fukada, H. P. Lemos, S. M. Vieira, M. H. Napimoga, M. M. Teixeira, A. R. Fraser, F. Y. Liew, I. B. McInnes, and F. Q. Cunha. 2008. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum. 58:2030-2040.
41. Tincani, A., L. Andreoli, C. Bazzani, D. Bosiso, and S. Sozzani. 2007. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun. Rev. 7:1-7.
42. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397-440.
43. Passos, G. F., E. S. Fernandes, M. M. Campos, J. G. Araújo, J. L. Pesquero, G. E. Souza, M. C. Avellar, M. M. Teixeira, and J. B. Calixto. 2004. Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J. Immunol. 172:1839-1847.
44. Fujiwara, K., S. Ohkawara, K. Takagi, M. Yoshinaga, and A. Matsukawa. 2002. Involvement of CXC chemokine growth-related oncogene-a in monosodium urate crystal-induced arthritis in rabbits. Lab. Invest. 82:1297-1304.
45. Ricci, J. A., W. F. Stewart, E. Chee, C. Leotta, K. Foley, and M. C. Hochberg. 2005. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum. 53:673-681.
46. Cunha, T. M., W. A. Verri, Jr., D. A. Valério, A. T. Guerrero, L. G. Nogueira, S. M. Vieira, D. G. Souza, M. M. Teixeira, S. Poole, S. H. Ferreira, and F. Q. Cunha. 2008. Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice. Eur. J. Pain 12:1059-1068.
47. Cunha, T. M., W. A. Verri, Jr., J. S. Silva, S. Poole, F. Q. Cunha, and S. H. Ferreira. 2005. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc. Natl. Acad. Sci. USA 102:1755-1760.
48. Sampaio, W. O., C. Henrique de Castro, R. A. Santos, E. L. Schiffrin, and R. M. Touyz. 2007. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50:1093-1098.
49. Nie, W., H. Yan, S. Li, Y. Zhang, F. Yu, W. Zhu, F. Fan, and J. Zhu. 2009. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Mol. Immunol. 46:355-361.
50. Snow, M. H., and T. R. Mikuls. 2005. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr. Opin. Rheumatol. 17:234-241.
51. Watson, D. J., T. Rhodes, and H. A. Guess. 2003. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J. Rheumatol. 30:1196-1202.
52. Pasceri, V., and E. T. Yeh. 1999. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100:2124-2126.
53. Wolfe, F., B. Freundlich, and W. L. Straus. 2003. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J. Rheumatol. 30:36-40.
54. Oppenheimer-Marks, N., and P. E. Lipsky. 1998. Adhesion molecules in rheumatoid arthritis. Springer Semin. Immunopathol. 20:95-114.
55. van der Helm-van Mil, A. H., J. Z. Wesoly, and T. W. Huizinga. 2005. Understanding the genetic contribution to rheumatoid arthritis. Curr. Opin. Rheumatol. 17:299-304.
56. Hanafy, S., N. J. Dagenais, W. F. Dryden, and F. Jamali. 2008. Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. Br. J. Pharmacol. 153:90-99.